India, March 17 -- Biopharmaceutical company Akeso Inc. (AKESF) said in a statement that its Penpulimab has been approved for the first-line treatment of recurrent or metastatic nasopharyngeal cancer or NPC, alongside chemotherapy. The approval has been secured from the National Medical Products Administration or NMPA.
The company said that earlier Penpulimab was approved as a third-line treatment for advanced nasopharyngeal cancer. According to Akeso, the new approval means that the drug can offer patients continuous immunotherapy options across all stages of NPC, whether it is first line therapy or third-line treatment.
The company said with this approval, it is the fourth indication for Penpulimab. Along with the two NPC indications, t...